H
Halia Therapeutics
Treating neurodegeneration and inflammatory diseases by targeting the nlrp3 inflammasome
About Halia Therapeutics
Halia Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and neurodegenerative diseases. The company's research is centered on the NLRP3 inflammasome, a key component of the innate immune system that is implicated in the inflammatory response associated with numerous conditions.
Their therapeutic strategy involves the development of small molecule inhibitors that target the NLRP3 inflammasome. One of their lead candidates, HT-6184, is a first-in-class inhibitor designed to address 'metaflammation,' the chronic, low-grade inflammation linked to obesity and other metabolic diseases. The company is also advancing treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease through its LRRK2 inhibitor program, with its candidate HT-4253 targeting neuroinflammation.
The company's business model is based on the discovery and clinical development of novel drug candidates. By progressing these candidates through early-stage clinical trials, Halia Therapeutics aims to establish proof-of-concept and then seek partnerships or licensing agreements with larger pharmaceutical firms for late-stage development and commercialization. A notable collaboration includes receiving a 'Golden Ticket' from Novo Nordisk to advance research in obesity and metabolic syndromes.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2024 | $30M | $120M | Todd Pedersen | ↗ |
| SERIES BOther financing | Dec 2022 | $12M | $49M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Halia Therapeutics is 2.4K monthly website visits, up 192.7% over the last three months. Halia Therapeutics's team grew 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Halia Therapeutics in the Lehi ecosystem
The Halia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Todd Pedersen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Halia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Halia Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








